Assessment and management of hypertension in patients with type 2 diabetes.
BACKGROUND
Hypertension is a major risk factor for adverse outcomes in type 2 diabetes and an important target for intervention. Despite this, the management of blood pressure (BP) remains suboptimal, particularly in patients at increased risk for cardiovascular and chronic kidney disease. The aim of this study was to estimate the frequency of hypertension and its management in consecutive clinic-based samples of patients with type 2 diabetes in Australian primary care.


METHODS
BP levels and antihypertensive management strategies were compared in patients with type 2 diabetes recruited as part of the Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes (DEMAND) study in 2003 (n = 1831) and the National Evaluation of the Frequency of Renal impairment cO-existing with Non-insulin-dependent diabetes (NEFRON) study in 2005 (n = 3893). Systolic BP levels and the use of antihypertensive therapies were examined in patients with and without chronic kidney disease.


RESULTS
The patient characteristics in both studies were similar in that more than 80% of patients in both studies were hypertensive. Systolic BP targets of < or =130 mmHg were achieved in approximately half of all treated patients in both studies. However, the use of antihypertensive therapy either alone or in combination increased from 70.4% in DEMAND to 79.5% in NEFRON 2 years later (P < 0.001). Despite this, antihypertensive therapy continued to be underutilized in high-risk groups, including in those with established chronic kidney disease.


CONCLUSIONS
The DEMAND and NEFRON studies both show that BP control is achievable in Australian general practice, with more than half of all patients seeing their general practitioners achieving a target systolic BP < or =130 mmHg. However, more needs to be done to further reduce BP levels, particularly in patients at high risk of adverse outcomes.
Thomas
M C
MC
Danielle Alberti Memorial Centre for Diabetes Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia.
Atkins
R
R
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001315:Australia; D002318:Cardiovascular Diseases / Q000209:etiology; D048909:Diabetes Complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000209:etiology; D008297:Male; D015995:Prevalence; D011320:Primary Health Care; D012307:Risk Factors; D013599:Systole
D000959:Antihypertensive Agents